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OBJECTIVES The study was done to determine whether eptifibatide, a platelet glycoprotein (GP) IIb/IIIa
antagonist, prevents ischemic complications following percutaneous coronary interventions
(PCIs) in women as well as in men.
BACKGROUND Eptifibatide reduces ischemic complications after nonurgent coronary stent interventions.
METHODS We compared outcomes in women (n 562) and men (n 1,502) enrolled in the Enhanced
Suppression of the Platelet GP IIb/IIIa Receptor with Integrilin Therapy (ESPRIT) trial of
double-bolus eptifibatide during PCI.
RESULTS Women in the ESPRIT trial were older, and more frequently had hypertension, diabetes
mellitus, or acute coronary syndromes, but were less likely to have prior PCI or coronary
artery bypass graft surgery. The primary end point, a composite at 48 h of death, myocardial
infarction (MI), urgent target vessel revascularization (TVR), and unplanned GP IIb/IIIa use,
occurred in 10.5% of women and 7.9% of men (p  0.082). The composite of death, MI, or
TVR after one year occurred in 24.5% of women compared with 18% of men (p  0.0008).
At 48 h, eptifibatide reduced the composite of death, MI, and TVR from 14.5% to 6.0% in
women versus 9.0% to 6.8% in men. At one year, these differences persisted: 28.9% versus
20.0% for women and 19.5% versus 16.6% for men. No statistical interaction existed between
treatment and gender at either 48 h (p  0.063) or one year (p  0.2). Bleeding occurred
more commonly in women (5.5% vs. 2.6%, p  0.002), and was more common in
eptifibatide-treated women. After adjustment for age, weight, and hypertension, no interac-
tion between treatment and gender was present.
CONCLUSIONS Eptifibatide is effective to prevent ischemic complications of PCI in women and may
eliminate gender-related differences in PCI outcomes. (J Am Coll Cardiol 2002;40:
1085–91) © 2002 by the American College of Cardiology Foundation
Because both the presence and the impact of coronary artery
disease are increasingly recognized in women, the number
of percutaneous coronary interventions (PCIs) performed in
women is likely to increase as well (1). Moreover, recent
studies have reported significant differences in prognostic
factors and adverse clinical outcomes in women who un-
dergo PCIs and coronary stenting as compared with men
(2,3). Although numerous studies have demonstrated that
antagonists of platelet glycoprotein (GP) IIb/IIIa prevent
myocardial infarction (MI) and other ischemic events when
used during PCI (4–7) the efficacy of GP IIb/IIIa antago-
nists in women has remained controversial. A recent meta-
analysis of three clinical trials using abciximab observed that
the effect of abciximab was not different for men versus
women undergoing PCI (2). However, at the same time,
retrospective analysis of data from the large Platelet Glyco-
protein IIb/IIIa in Unstable Angina: Receptor Suppression
Using Integrilin Therapy, (PURSUIT) study of patients
with acute coronary syndromes suggested that treatment
with the cyclic heptapeptide GP IIb/IIIa antagonist eptifi-
batide may have been more effective in men than in women
(8). Whether these observations represent true biologic
differences in platelet aggregation mechanisms, or in the
biology of the arterial wall, between men and women (9), or
whether they are due to anthropometric differences or to
heterogeneous patterns of clinical care in men and women is
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not clear. To pursue this question further, we analyzed data
from a large trial of double-bolus doses of eptifibatide in
patients undergoing elective stent placement.
METHODS
Study population. The methods and results of the En-
hanced Suppression of the Platelet GP IIb/IIIa Receptor
with Integrilin Therapy (ESPRIT) trial have been previ-
ously published (7). Patients undergoing elective PCI were
eligible if there were no contraindications to treatment with
a platelet GP IIb/IIIa antagonist and the operating physi-
cian was uncertain whether a platelet GP IIb/IIIa antagonist
was indicated. Patients were treated with aspirin 325 mg,
and a thienopyridine. Heparin was given as 60 U/kg, not to
exceed 6,000 U. Patients received either a placebo or
eptifibatide given as two 180-g/kg bolus doses separated
by 10 min, and a 2-g/kg/min infusion continued until
hospital discharge or up to 18 to 24 h. The target activated
clotting time was 200 to 300 s. The primary study end point
was the composite at 48 h of death, MI, urgent target vessel
revascularization (TVR), or “bail-out” use of eptifibatide.
Patients were also followed for the composite of death, MI,
or TVR at one year. Myocardial infarction was present
when two or more values of creatine kinase-muscle brain
isoenzyme within the first 24 h after PCI were at least three
times the upper limit of normal. Complications related to
therapy were evaluated by the rates of bleeding, blood
transfusion, and stroke for 48 h or hospital discharge.
Hemorrhages were classified as major or minor according to
the criteria of the Thrombolysis In Myocardial Infarction
(TIMI) study group (10).
Statistical analyses. Patient data were collected as part of
the overall ESPRIT trial. Continuous baseline characteris-
tics and clinical outcomes were reported as medians with
25th and 75th percentiles. Categorical variables were ana-
lyzed using Likelihood Ratio Chi-Square and Fisher exact
tests. Continuous variables were analyzed using the Mann-
Whitney U test. The cumulative event rate over time was
estimated using the Kaplan-Meier method with the time to
the first event of death, MI, or TVR used as the outcome
variable. The Likelihood Chi-Square statistic was used to
test the interaction between gender and treatment with
eptifibatide following an adjustment for baseline character-
istics, at 48 h and 30 days. Baseline characteristics included
age, history of diabetes, acute ST-elevation, MI 7 days,
prior percutaneous transluminal coronary angioplasty
(PTCA), target pre-thrombus, target pre-TIMI flow, and
stable angina. Unadjusted Cox proportional hazards survival
models were used to compute hazard ratios for the 48-h
composite end point for men versus women on eptifibatide
or placebo. Adjusted Cox proportional hazards survival
models were created to adjust for the differences in the
baseline characteristics and treatment for the one-year
primary end point. Baseline characteristics for the one-year
primary end point included age, heparin pre-PCI, target
pre-thrombus, treatment, and interaction of treatment and
age. Adjustments were also made for body weight. Logistic
regression models for bleeding were created to adjust for
covariates that included age, weight, gender, treatment, and
prior hypertension, which were derived from a previously
developed model (11). A two-tailed p value 0.05 was
considered statistically significant.
RESULTS
A total of 2,064 patients, 562 women and 1,502 men, were
enrolled in the ESPRIT trial between June 3, 1999, and
February 4, 2000. Women were more likely to be older,
lighter in weight, have hypertension, or diabetes and were
less likely to have had a prior MI or coronary artery bypass
graft surgery (CABG). No difference existed between gen-
ders in the proportion of vessels narrowed 70% (p 
0.076). Percutaneous coronary interventions were per-
formed in more than 98% of enrolled patients, with stents
being used at a rate of 96% in both genders. No differences
existed in procedural variables between women and men,
with the exception that dilation of the right coronary artery
was slightly more common in men (Table 1). Angiographic
complications were uncommon and also occurred with
similar frequencies among women and men (Table 2). No
evidence was seen of statistical interaction between treat-
ment and gender for any of the angiographic complications.
Various elements of the composite end point tended to
occur more frequently in women within the first 48 h (Fig.
1). The difference in the event rates at 48 h was not different
between the two genders (women vs. men: 10.5% vs. 7.9%,
p  0.082). However, the event rate for death, MI, and
TVR was higher in women at one year (24.5% vs. 18%;
hazards ratio [HR]  1.42, 95% confidence interval [CI]
1.16, 1.75, p  0.0008). Correction for body weight altered
these rates by 0.4% or less. After adjustment for other
baseline differences between men and women, the HR for
the composite of ischemic events was still higher in women
Abbreviations and Acronyms
CABG  coronary artery bypass graft surgery
CI  confidence interval
ESPRIT  Enhanced Suppression of the Platelet GP
IIb/IIIa Receptor with Integrilin Therapy
GP  glycoprotein
HR  hazards ratio
MI  myocardial infarction
OR  odds ratio
PCI  percutaneous coronary intervention
PTCA  percutaneous transluminal coronary
angioplasty
PURSUIT  Platelet Glycoprotein IIb/IIIa in Unstable
Angina: Receptor Suppression Using
Integrilin Therapy
TIMI  Thrombolysis In Myocardial Infarction
trial
TVR  target vessel revascularization
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both at 48 h (HR for women vs. men 1.39 [1.0, 1.93]) and
one year (HR for women vs. men 1.36 [1.09, 1.69]).
Treatment with eptifibatide resulted in a reduction in the
composite end point in women and men (Fig. 2). After
eptifibatide treatment, the event rates at 48 h were very
similar in women and men (6.1% and 6.8%, respectively).
The one-year composite rate of death, MI, or TVR was
higher in women receiving placebo versus eptifibatide
(28.9% vs. 20%). The directionality of treatment effect was
the same in women and men (20% vs. 16.6%), although the
relative reduction in risk was greater in women (30% vs.
15%). No statistical interaction existed between treatment
and gender at 48 h (p  0.063) or at one year (p  0.2).
Survival free of death or MI was also greater in eptifibatide-
treated women as compared to placebo-treated women (Fig.
3). As for the primary composite end point, no evidence was
seen of statistical interaction between gender and treatment
at 48 h (p 0.32) and one year (p 0.21). The interactions
at one year also remained nonsignificant after adjustment
for weight.
Major bleeding occurred more frequently in women than
in men 8/506 (1.6%) and 9/1,364 (0.66%), respectively
(odds ratio [OR] 2.46, 95% CI 0.94, 6.43). For major or
minor bleeding, the frequencies were 28/506 (5.5%) versus
36/1,364 (2.6%) (OR 2.19, 95% CI 1.32, 3.63; p  0.002).
Among women, major or minor bleeding was more com-
mon in patients treated with eptifibatide, whereas in men
the event rates were similar regardless of treatment (Table
2). After adjustment for weight, age, and hypertension
according to the GUSTO model, these differences in major
or minor bleeding between men and women were nonsig-
nificant (OR 1.6, 95% CI 0.9, 2.84; p  0.11). In the
adjusted model, no interaction existed between gender and
major/minor bleeding. In the unadjusted model, no statis-
Table 1. Patients’ Baseline Characteristics
Women
(n  562)
Men
(n  1,502) p Value
Demographics
Age (yrs) 65 (57,74) 61 (53,79)  0.001*
Weight (kg) 75 (64,85) 88 (78,99)  0.001*
Previous MI 143, 25% 509, 34%  0.001*
Stable angina 190, 40% 604, 34%  0.008*
Hypertension 381, 68% 832, 56%  0.001*
Diabetes 157, 28% 262, 17%  0.001*
Previous CABG 33, 6% 178, 12%  0.001*
Nonsmoker 234, 42% 362, 24%  0.001*
High cholesterol 331, 59% 868, 58%  0.66
Previous PCI 126, 22% 357, 24%  0.52
Single-vessel disease 452, 80% 1,205, 80.2% 0.92
Angiographic characteristics
Infusion duration (h) 18.4 (18.0, 20.3) 18.4 (18.0, 20.1) 0.58
PCI performed, n, % 555, 98.8 1,485, 98.9 0.83
Stent placed, n, % 541, 96.3 1,442, 96.0 0.78
Thienopyridine, n, % 551, 98.2 1,464, 97.5 0.31
Maximal ACT (s) 284 (127,835) 278 (21,788) 0.90
Vessel dilated
LAD 231, 41.1% 666, 44.3% 0.187
RCA 239, 37.3% 560, 42.5% 0.29
CFX/Ramus 159, 28.3% 492, 32.7% 0.052
Continuous variables are reported as median (25th, 75th percentiles).
ACT  activated clotting time; CABG  coronary artery bypass graft surgery;
CFX  circumflex; LAD  left anterior descending; MI  myocardial infarction;
PCI  percutaneous coronary intervention; RCA  right coronary artery.
Table 2. Patients’ Complications
Women
(n  562)
Men
(n  1,502) p Value
Angiographic
Major dissection 27 (5%) 50 (3%) 0.12
Abrupt closure 6 (1%) 15 (1%) 0.89
No reflow 6 (1%) 21 (1%) 0.56
Thrombosis 7 (1%) 18 (1%) 0.93
Distal embolization 2 (1%) 13 (1%) 0.78
Side branch closure 22 (4%) 63 (4%) 0.22
Women (n  506) Men (n  1,364)
Eptifibatide Placebo Eptifibatide Placebo
Bleeding
Major 6 (2.36%) 2 (0.79%) 7 (0.99%) 2 (0.30%) 0.062
Minor 14 (5.51%) 6 (2.38%) 15 (2.1%) 12 (1.82%) 0.015
The p values refer to differences between women and men.
Figure 1. Individual selected elements of the composite end point at 48 h
for men and women. MI  myocardial infarction; uTVR  urgent target
vessel revascularization.
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tical interaction existed between gender and treatment for
major bleeding (p  0.94), minor bleeding (p  0.26), or
major or minor bleeding (p 0.26). The most common site
for major or minor non–CABG-related bleeding was at the
femoral access site (36% in men and 64% in women).
DISCUSSION
We found that treatment with a double-bolus regimen of
the platelet GP IIb/IIIa antagonist eptifibatide offered
similar protection against serious ischemic events among
women and men. Event-free survival was better in women
receiving eptifibatide compared with placebo treatment. At
the end of 48 h there was a trend toward greater benefit in
women than in men, perhaps reflecting the higher overall
risk in women. At this point, eptifibatide reduced the
frequency of events in women to rates comparable to those
observed in men. However, over the course of the ensuing
year, the rates of the composite end point diverged, and the
evidence of interaction between treatment and gender be-
came less, suggesting that the need for further revascular-
ization and perhaps the overall risk of coronary heart disease
in women remained higher than in men.
Importance of gender differences in PCI. Coronary heart
disease is the leading cause of mortality and morbidity in the
U.S. in both women and in men. After accounting for the
increasing proportion of women in the aging population,
each year more women die of cardiovascular disease than
men (12). Comparison of reports from a decade ago with
those of the past several years would suggest that coronary
artery disease is increasingly recognized in women (13,14).
Consequently, the proportion of female patients undergoing
PCI has increased over the past two decades (1,15). Most
investigations have reported differences in clinical charac-
teristics between women and men undergoing PCI. As in
the current study, women undergoing PCIs are more likely
to be older, and more likely to have hypertension, diabetes
mellitus, and lower rates of prior MI and CABG (2,3,16–
20).
Whether there are in fact differences in clinical outcomes
following PCI is less clear. In the early experience, female
gender was reported to be an independent predictor of both
abrupt vessel closure (21) and of mortality in the event of a
procedural complication (22). Long-term follow-up in the
second National Heart, Lung, and Blood Institute PTCA
Registry revealed worse outcomes four years after an index
procedure in women. However, this finding was partially
explained by the presence of more risk factors for mortality
(23). Bell et al. (16) observed that, in the years preceding the
frequent use of GP IIb/IIIa antagonists, procedural success
rates were similar in women and men, but that female
gender was a weak but independent predictor of in-hospital
mortality. Correction for body surface area further weak-
ened this association. Jacobs et al. (3) observed that within
the Bypass Angioplasty Revascularization Investigation
Figure 2. Kaplan-Meier estimates of the composite of death, myocardial infarction, or target vessel revascularization during the first year, according to
gender and treatment with eptifibatide.
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(BARI), five-year survival among women undergoing PCI
was nearly identical to that of men. However, when the
randomized cohort from this trial was pooled with a registry
cohort, female gender proved to be an independent predic-
tor of improved outcome. More appropriate selection of
patients and the availability of intracoronary stents may have
led to reductions in the observed differences between men
and women (17,20). However, vascular complications and
postprocedural acute renal failure remain more common in
women (18,20).
Comparison with other studies. Although periprocedural
morbidity and mortality following PCI are prevented by GP
IIb/IIIa antagonists, few investigators have compared the
protective effects of GP IIb/IIIa antagonists in men and
women. In a pooled analysis from the Evaluation of Platelet
Inhibition on Ischemic Complications of PTCA (EPIC),
Evaluation in PTCA to Improve Long-Term Outcome
with Abciximab GP IIb/IIIa Blockade (EPILOG), and
Evaluation of Platelet IIb/IIIa Inhibitor for Stenting
(EPISTENT) trials, the primary end point, a composite of
death, MI, and urgent TVR at 30 days, was reduced in
patients treated with abciximab from 11.3% to 5.8% (p 
0.001) in men compared with a reduction from 12.7% to
6.5% (p  0.001) in women. This benefit persisted to one
year. However, women in this analysis were also more prone
to develop major and minor bleeding complications (2).
Unlike the current analysis, data from the PURSUIT trial
suggested an interaction between gender and eptifibatide
treatment effect consistent with more bleeding as well as less
protection against ischemia in women. Several factors may
account for the different observations made in PURSUIT
and ESPRIT. Foremost among these are the homogeneity
of the population enrolled and the therapeutic approach in
the ESPRIT trial compared with the heterogeneity of the
population and clinical practices in PURSUIT.
As a “real world” trial, PURSUIT permitted the care
provider wide latitude in patient enrollment and treatment
of patients with suspected (but not necessarily confirmed)
acute coronary syndromes. Whether and when to perform
PCI as well as procedural details were left to individual PCI
operators; 25% of patients in PURSUIT underwent coro-
nary intervention, and approximately 12.5% underwent
intervention while receiving the study drug (24). Addition-
ally, 60% of the interventions in PURSUIT involved place-
ment of an intracoronary stent compared with 96% in
ESPRIT. Moreover, PURSUIT was performed on an
international basis, and there appeared to be important
interactions between gender and regional clinical practice.
In North America, for example, the frequency of early (72
h) intervention was highest in PURSUIT, and the outcomes
of men and women were not different (25). ESPRIT was
performed entirely in North America. By design, the strat-
egies tested in ESPRIT represent a considerably more
homogeneous treatment pattern. A recent meta-analysis of
GP IIb/IIIa antagonists in patients with acute coronary
syndromes confirmed these findings. A beneficial treatment
Figure 3. Kaplan-Meier estimates of death or myocardial infarction during the first year according to gender and eptifibatide treatment.
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effect was observed in men, but not in women. However,
when the analysis was restricted to patients with objective
markers of active ischemia (i.e., troponin-T elevation), no
interaction existed between gender and GP IIb/IIIa treat-
ment (26).
It is important to emphasize that ESPRIT included a
population of patients largely undergoing nonurgent proce-
dures using modern interventional techniques. Approxi-
mately 96% of patients enrolled in ESPRIT received intra-
coronary stents and postprocedural treatment with a
thienopyridine. The current data, then, performed in an
extremely homogeneously managed population, indicate
that the clinical benefit of GP IIb/IIIa antagonism with
eptifibatide is likely to be similar in women and in men.
Study limitations. The current analysis has three limita-
tions. First, by design, ESPRIT lacked adequate statistical
power to analyze results for each gender independently.
Second, because ESPRIT was designed to collect informa-
tion rapidly in a large population, there was no angiographic
core laboratory, and the amount of angiographic data is
consequently limited. Detailed comparison of angiographic
differences between women and men is therefore not pos-
sible within this data set. More detailed data concerning
angiographic characteristics of lesions dilated and of coro-
nary arterial diameters would have been useful to under-
stand the one-year outcomes, particularly as postprocedural
lesion diameter is a major determinant of restenosis (27).
Similarly, we did not inquire about menopausal status or the
use of hormone replacement therapy. Finally, the ESPRIT
population was limited to patients undergoing nonurgent
procedures and did not include patients undergoing primary
PCI.
Clinical implications. Even in the modern era of PCI,
periprocedural ischemic events are more common among
women than among men. Double-bolus eptifibatide in the
setting of low-dose-adjusted heparin, aspirin, and a thien-
opyridine prevented ischemic events similarly in both
women and men immediately after PCI, with sustained
results up to one year. Although bleeding after eptifibatide
treatment was more common in women than in men, no
difference was seen after adjustment for previously identified
major covariates. These findings suggest that platelet GP
IIb/IIIa antagonism with eptifibatide is an effective therapy
to prevent ischemic complications in women undergoing
PCIs.
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